Japan’s Ministry of health, Labour and Welfare issued an expedited emergency approval on 10 February for Pfizer Inc.’s oral antiviral Paxlovid, for use in mild-to-moderate COVID-19 patients aged 12 or older and weighing at least 40kg and at high risk for developing severe symptoms.
The therapy, comprising the 3CL protease inhibitor nirmatrelvir and existing antiviral ritonavir, was approved in the US in December and the EU in January, and the Japan nod came immediately after a positive opinion from an advisory panel the same day, following an approval application made on 14 January
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?